Severe Skin Toxicity Caused by Sequential Anti-PD-1 Antibody and Alectinib in Non-small-cell Lung Cancer: A Report of Two Cases and a Literature Review
Immune checkpoint inhibitors (ICIs) have demonstrated marked efficacy in some cancer patients, but they may cause various severe immune-related adverse events. Alectinib is a second-generation anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitor (TKI) approved for ALK-rearranged non-small-cell...
Gespeichert in:
| Veröffentlicht in: | Internal Medicine 2022/06/01, Vol.61(11), pp.1735-1738 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1738 |
|---|---|
| container_issue | 11 |
| container_start_page | 1735 |
| container_title | Internal Medicine |
| container_volume | 61 |
| creator | Nishiyama, Akihiro Hattori, Yoshihiro Takeuchi, Shinji Tanimoto, Azusa Satouchi, Miyako Murayama, Toshinori Yano, Seiji |
| description | Immune checkpoint inhibitors (ICIs) have demonstrated marked efficacy in some cancer patients, but they may cause various severe immune-related adverse events. Alectinib is a second-generation anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitor (TKI) approved for ALK-rearranged non-small-cell lung cancer (NSCLC). Alectinib is said to be safer than other TKIs. We conducted an investigator-initiated trial of alectinib, which also has RET kinase-inhibitory activity, against RET-rearranged NSCLC. Two RET-rearranged NSCLC patients experienced severe skin toxicity with alectinib after first undergoing anti-PD-1 antibody treatment with an ICI. These findings suggest that we should carefully follow patients for adverse effects of targeted drugs following ICI treatment. |
| doi_str_mv | 10.2169/internalmedicine.7472-21 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9259316</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2672385731</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5821-95ad7f55f975250968fe89a7053975f6327b19d75801bb04e32a5f4d4bdd41f43</originalsourceid><addsrcrecordid>eNplkV1v0zAUhi0EYt3gLyBL3HCT4Y84jrlAqsqnVDG0lmvLSU46l9Tu7KSjv2R_F2ctFYybY8t-zmu_50UIU3LJaKHeWtdDcKbbQGNr6-BS5pJljD5BE8pzlUnGxVM0IYqWGUvlDJ3HuCaEl1Kx5-iM5yXhRJEJul_ADgLgxU_r8NL_SnL9Hs_MEKHB1R4v4HYA11vT4Wlasu8fMvqwq3yzx8Y1eNpB3VtnK5wUvnmXxY3puqyGrsPzwa2SmKshvMNTfA1bH3rsW7y88-k8QnyQMHhukyHTD-kn17CzcPcCPWtNF-Hlcb1APz59XM6-ZPOrz19n03lWi5LRTAnTyFaIVknBBFFF2UKpjCSCp5O24ExWVDVSlIRWFcmBMyPavMmrpslpm_ML9P6gux2qNM06eQ2m09tgNybstTdW_3vj7I1e-Z1WTChOiyTw5igQfBpV7PXGxtG8ceCHqFlBSJkKJwl9_Qhd-2GMcaRSZKWQnCaqPFB18DEGaE-foUSP6evH6esx_XSVWl_9bebU-CfuBFwdgHXszQpOgAm9rTv4X7mgmtKxHp84kfWNCRoc_w1bcc3L</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2672385731</pqid></control><display><type>article</type><title>Severe Skin Toxicity Caused by Sequential Anti-PD-1 Antibody and Alectinib in Non-small-cell Lung Cancer: A Report of Two Cases and a Literature Review</title><source>J-STAGE Free</source><source>MEDLINE</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Nishiyama, Akihiro ; Hattori, Yoshihiro ; Takeuchi, Shinji ; Tanimoto, Azusa ; Satouchi, Miyako ; Murayama, Toshinori ; Yano, Seiji</creator><creatorcontrib>Nishiyama, Akihiro ; Hattori, Yoshihiro ; Takeuchi, Shinji ; Tanimoto, Azusa ; Satouchi, Miyako ; Murayama, Toshinori ; Yano, Seiji</creatorcontrib><description>Immune checkpoint inhibitors (ICIs) have demonstrated marked efficacy in some cancer patients, but they may cause various severe immune-related adverse events. Alectinib is a second-generation anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitor (TKI) approved for ALK-rearranged non-small-cell lung cancer (NSCLC). Alectinib is said to be safer than other TKIs. We conducted an investigator-initiated trial of alectinib, which also has RET kinase-inhibitory activity, against RET-rearranged NSCLC. Two RET-rearranged NSCLC patients experienced severe skin toxicity with alectinib after first undergoing anti-PD-1 antibody treatment with an ICI. These findings suggest that we should carefully follow patients for adverse effects of targeted drugs following ICI treatment.</description><identifier>ISSN: 0918-2918</identifier><identifier>EISSN: 1349-7235</identifier><identifier>DOI: 10.2169/internalmedicine.7472-21</identifier><identifier>PMID: 34803090</identifier><language>eng</language><publisher>Japan: The Japanese Society of Internal Medicine</publisher><subject>alectinib ; Anaplastic Lymphoma Kinase ; anti-PD-1 antibody ; Carbazoles ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - pathology ; Case Report ; Humans ; ICIs ; Immune checkpoint inhibitors ; Immunosuppressive agents ; Internal medicine ; Literature reviews ; Lung Neoplasms - drug therapy ; Lung Neoplasms - pathology ; Non-small cell lung carcinoma ; Patients ; PD-1 protein ; Piperidines ; Protein Kinase Inhibitors - adverse effects ; Protein-tyrosine kinase ; Receptor Protein-Tyrosine Kinases ; Ret protein ; severe skin toxicity ; Small cell lung carcinoma ; Toxicity</subject><ispartof>Internal Medicine, 2022/06/01, Vol.61(11), pp.1735-1738</ispartof><rights>2022 by The Japanese Society of Internal Medicine</rights><rights>Copyright Japan Science and Technology Agency 2022</rights><rights>Copyright © 2022 by The Japanese Society of Internal Medicine</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5821-95ad7f55f975250968fe89a7053975f6327b19d75801bb04e32a5f4d4bdd41f43</citedby><cites>FETCH-LOGICAL-c5821-95ad7f55f975250968fe89a7053975f6327b19d75801bb04e32a5f4d4bdd41f43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259316/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259316/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,1877,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34803090$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nishiyama, Akihiro</creatorcontrib><creatorcontrib>Hattori, Yoshihiro</creatorcontrib><creatorcontrib>Takeuchi, Shinji</creatorcontrib><creatorcontrib>Tanimoto, Azusa</creatorcontrib><creatorcontrib>Satouchi, Miyako</creatorcontrib><creatorcontrib>Murayama, Toshinori</creatorcontrib><creatorcontrib>Yano, Seiji</creatorcontrib><title>Severe Skin Toxicity Caused by Sequential Anti-PD-1 Antibody and Alectinib in Non-small-cell Lung Cancer: A Report of Two Cases and a Literature Review</title><title>Internal Medicine</title><addtitle>Intern. Med.</addtitle><description>Immune checkpoint inhibitors (ICIs) have demonstrated marked efficacy in some cancer patients, but they may cause various severe immune-related adverse events. Alectinib is a second-generation anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitor (TKI) approved for ALK-rearranged non-small-cell lung cancer (NSCLC). Alectinib is said to be safer than other TKIs. We conducted an investigator-initiated trial of alectinib, which also has RET kinase-inhibitory activity, against RET-rearranged NSCLC. Two RET-rearranged NSCLC patients experienced severe skin toxicity with alectinib after first undergoing anti-PD-1 antibody treatment with an ICI. These findings suggest that we should carefully follow patients for adverse effects of targeted drugs following ICI treatment.</description><subject>alectinib</subject><subject>Anaplastic Lymphoma Kinase</subject><subject>anti-PD-1 antibody</subject><subject>Carbazoles</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Case Report</subject><subject>Humans</subject><subject>ICIs</subject><subject>Immune checkpoint inhibitors</subject><subject>Immunosuppressive agents</subject><subject>Internal medicine</subject><subject>Literature reviews</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - pathology</subject><subject>Non-small cell lung carcinoma</subject><subject>Patients</subject><subject>PD-1 protein</subject><subject>Piperidines</subject><subject>Protein Kinase Inhibitors - adverse effects</subject><subject>Protein-tyrosine kinase</subject><subject>Receptor Protein-Tyrosine Kinases</subject><subject>Ret protein</subject><subject>severe skin toxicity</subject><subject>Small cell lung carcinoma</subject><subject>Toxicity</subject><issn>0918-2918</issn><issn>1349-7235</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNplkV1v0zAUhi0EYt3gLyBL3HCT4Y84jrlAqsqnVDG0lmvLSU46l9Tu7KSjv2R_F2ctFYybY8t-zmu_50UIU3LJaKHeWtdDcKbbQGNr6-BS5pJljD5BE8pzlUnGxVM0IYqWGUvlDJ3HuCaEl1Kx5-iM5yXhRJEJul_ADgLgxU_r8NL_SnL9Hs_MEKHB1R4v4HYA11vT4Wlasu8fMvqwq3yzx8Y1eNpB3VtnK5wUvnmXxY3puqyGrsPzwa2SmKshvMNTfA1bH3rsW7y88-k8QnyQMHhukyHTD-kn17CzcPcCPWtNF-Hlcb1APz59XM6-ZPOrz19n03lWi5LRTAnTyFaIVknBBFFF2UKpjCSCp5O24ExWVDVSlIRWFcmBMyPavMmrpslpm_ML9P6gux2qNM06eQ2m09tgNybstTdW_3vj7I1e-Z1WTChOiyTw5igQfBpV7PXGxtG8ceCHqFlBSJkKJwl9_Qhd-2GMcaRSZKWQnCaqPFB18DEGaE-foUSP6evH6esx_XSVWl_9bebU-CfuBFwdgHXszQpOgAm9rTv4X7mgmtKxHp84kfWNCRoc_w1bcc3L</recordid><startdate>20220601</startdate><enddate>20220601</enddate><creator>Nishiyama, Akihiro</creator><creator>Hattori, Yoshihiro</creator><creator>Takeuchi, Shinji</creator><creator>Tanimoto, Azusa</creator><creator>Satouchi, Miyako</creator><creator>Murayama, Toshinori</creator><creator>Yano, Seiji</creator><general>The Japanese Society of Internal Medicine</general><general>Japan Science and Technology Agency</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220601</creationdate><title>Severe Skin Toxicity Caused by Sequential Anti-PD-1 Antibody and Alectinib in Non-small-cell Lung Cancer: A Report of Two Cases and a Literature Review</title><author>Nishiyama, Akihiro ; Hattori, Yoshihiro ; Takeuchi, Shinji ; Tanimoto, Azusa ; Satouchi, Miyako ; Murayama, Toshinori ; Yano, Seiji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5821-95ad7f55f975250968fe89a7053975f6327b19d75801bb04e32a5f4d4bdd41f43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>alectinib</topic><topic>Anaplastic Lymphoma Kinase</topic><topic>anti-PD-1 antibody</topic><topic>Carbazoles</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Case Report</topic><topic>Humans</topic><topic>ICIs</topic><topic>Immune checkpoint inhibitors</topic><topic>Immunosuppressive agents</topic><topic>Internal medicine</topic><topic>Literature reviews</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - pathology</topic><topic>Non-small cell lung carcinoma</topic><topic>Patients</topic><topic>PD-1 protein</topic><topic>Piperidines</topic><topic>Protein Kinase Inhibitors - adverse effects</topic><topic>Protein-tyrosine kinase</topic><topic>Receptor Protein-Tyrosine Kinases</topic><topic>Ret protein</topic><topic>severe skin toxicity</topic><topic>Small cell lung carcinoma</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nishiyama, Akihiro</creatorcontrib><creatorcontrib>Hattori, Yoshihiro</creatorcontrib><creatorcontrib>Takeuchi, Shinji</creatorcontrib><creatorcontrib>Tanimoto, Azusa</creatorcontrib><creatorcontrib>Satouchi, Miyako</creatorcontrib><creatorcontrib>Murayama, Toshinori</creatorcontrib><creatorcontrib>Yano, Seiji</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Internal Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nishiyama, Akihiro</au><au>Hattori, Yoshihiro</au><au>Takeuchi, Shinji</au><au>Tanimoto, Azusa</au><au>Satouchi, Miyako</au><au>Murayama, Toshinori</au><au>Yano, Seiji</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Severe Skin Toxicity Caused by Sequential Anti-PD-1 Antibody and Alectinib in Non-small-cell Lung Cancer: A Report of Two Cases and a Literature Review</atitle><jtitle>Internal Medicine</jtitle><addtitle>Intern. Med.</addtitle><date>2022-06-01</date><risdate>2022</risdate><volume>61</volume><issue>11</issue><spage>1735</spage><epage>1738</epage><pages>1735-1738</pages><artnum>7472-21</artnum><issn>0918-2918</issn><eissn>1349-7235</eissn><abstract>Immune checkpoint inhibitors (ICIs) have demonstrated marked efficacy in some cancer patients, but they may cause various severe immune-related adverse events. Alectinib is a second-generation anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitor (TKI) approved for ALK-rearranged non-small-cell lung cancer (NSCLC). Alectinib is said to be safer than other TKIs. We conducted an investigator-initiated trial of alectinib, which also has RET kinase-inhibitory activity, against RET-rearranged NSCLC. Two RET-rearranged NSCLC patients experienced severe skin toxicity with alectinib after first undergoing anti-PD-1 antibody treatment with an ICI. These findings suggest that we should carefully follow patients for adverse effects of targeted drugs following ICI treatment.</abstract><cop>Japan</cop><pub>The Japanese Society of Internal Medicine</pub><pmid>34803090</pmid><doi>10.2169/internalmedicine.7472-21</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0918-2918 |
| ispartof | Internal Medicine, 2022/06/01, Vol.61(11), pp.1735-1738 |
| issn | 0918-2918 1349-7235 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9259316 |
| source | J-STAGE Free; MEDLINE; PubMed Central; PubMed Central Open Access |
| subjects | alectinib Anaplastic Lymphoma Kinase anti-PD-1 antibody Carbazoles Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Case Report Humans ICIs Immune checkpoint inhibitors Immunosuppressive agents Internal medicine Literature reviews Lung Neoplasms - drug therapy Lung Neoplasms - pathology Non-small cell lung carcinoma Patients PD-1 protein Piperidines Protein Kinase Inhibitors - adverse effects Protein-tyrosine kinase Receptor Protein-Tyrosine Kinases Ret protein severe skin toxicity Small cell lung carcinoma Toxicity |
| title | Severe Skin Toxicity Caused by Sequential Anti-PD-1 Antibody and Alectinib in Non-small-cell Lung Cancer: A Report of Two Cases and a Literature Review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T14%3A07%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Severe%20Skin%20Toxicity%20Caused%20by%20Sequential%20Anti-PD-1%20Antibody%20and%20Alectinib%20in%20Non-small-cell%20Lung%20Cancer:%20A%20Report%20of%20Two%20Cases%20and%20a%20Literature%20Review&rft.jtitle=Internal%20Medicine&rft.au=Nishiyama,%20Akihiro&rft.date=2022-06-01&rft.volume=61&rft.issue=11&rft.spage=1735&rft.epage=1738&rft.pages=1735-1738&rft.artnum=7472-21&rft.issn=0918-2918&rft.eissn=1349-7235&rft_id=info:doi/10.2169/internalmedicine.7472-21&rft_dat=%3Cproquest_pubme%3E2672385731%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2672385731&rft_id=info:pmid/34803090&rfr_iscdi=true |